Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Autor: Vaz Batista, M., Pérez-García, J.M., Cortez, P., Garrigós, L., Fernández-Abad, M., Gion, M., Martínez-Bueno, A., Saavedra, C., Teruel, I., Fernandez-Ortega, A., Servitja, S., Ruiz-Borrego, M., de la Haba-Rodríguez, J., Martrat, G., Pérez-Escuredo, J., Alcalá-López, D., Sampayo-Cordero, M., Braga, S., Cortés, J., Llombart-Cussac, A.

Publikováno v: In ESMO Open September 2024 9(9)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P040 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONGITUDINAL PREVALENCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN BREAST AND OVARIAN CANCER PATIENTS PRIOR AND AFTER RECEIVING CYTOTOXIC TREATMENT

Autor: Calvete, O., Mestre, J., Manzanares, A., Silverio, A., Ruiz, R., Aranda, J., Acha, P., Palomo, L., González, A. Pérez, Bergamino, M., Cirauqui, B., Quiroga, V., Felip, E., Margeli, M., Romeo, M., Martinez-Cardús, A., Teruel, I., Solé, F.

Publikováno v: In Leukemia Research May 2023 128 Supplement

Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment

Autor: Minguela, Alfredo, Vasco-Mogorron, Maria A., Campillo, Jose A., Cabanas, Valentin, Remigia, Maria J., Berenguer, Mercedes, Garcia-Garay, Maria C., Blanquer, Miguel, Cava, Catalina, Galian, Jose Antonio, Gimeno, Lourdes, Soto-Ramirez, Maria F., Martinez-Hernandez, Maria D., de la Rubia, Javier, Teruel, I, Ana, Muro, Manuel, Periago, Adela

Publikováno v: Am J Cancer Res
American Journal of Cancer Research
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Improved therapies in multiple myeloma (MM) have forced a constant risk stratification update, first Durie-Salmon, then international scoring systems (ISS), next revised-ISS (RISS) including high-risk cytogenetic abnormalities (HRCAs) such as del(17p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d3fd0c6650533becce8c808b464ac057
https://europepmc.org/articles/PMC8493371/

Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy (vol 12, 713, 2020)

Autor: Castellvi, M, Felip, E, Ezeonwumelu, IJ, Badia, R, Garcia-Vidal, E, Pujantell, M, Gutierrez-Chamorro, L, Teruel, I, Martinez-Cardus, A, Clotet, B, Riveira-Munoz, E, Margeli, M, Este, JA, Ballana, E

Publikováno v: Cancers
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The authors wish you make the following corrections to this paper[...].

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f99a5a76fa22848235a4ce28165dcc00
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3210